US · Healthcare · Biotechnology
EPS came in at -0.81 against a street estimate of -0.90 — a beat of 10.0%.
Analysts rate Intellia Therapeutics Inc a buy (22 buy, 6 hold, 1 sell out of 29) with an average price target of $25.94.
| Fund | Stake |
|---|---|
| ARK Investment Management LLC | 10.38% |
| BlackRock Inc | 8.70% |
| State Street Corp | 4.95% |
| Vanguard Portfolio Management, LLC | 4.45% |
| D. E. Shaw & Co LP | 4.10% |
| Vanguard Capital Management, LLC | 3.64% |
| Two Sigma Investments LLC | 3.37% |
| Regeneron Pharmaceuticals Inc | 2.65% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q2 2026 | 2026-06-15 |
| Shareholder vote results · Q2 2026 | 2026-06-10 |
| Quarterly report · Q1 2026 | 2026-05-11 |
| Results announced · Q2 2026 | 2026-05-11 |
| Results announced · Q2 2026 | 2026-04-30 |
| Proxy statement · Q2 2026 | 2026-04-30 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Intellia Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.